By Evercyte GmbH
To get in touch with Evercyte GmbH, simply fill out the form below.
Subscribe to Supplier
Evercyte contributing to inaugural MOVE Symposium
Vienna, Austria: – Innovative biotech manufacturer Evercyte will be a prominent presence as a scientific contributor at the inaugural symposium in Malaga, Spain, of the recently formed MOVE consortium for collaborative extracellular vesicle (EV) research.
Evercyte R&D scientist Dr. Marieke Roefs will give an oral presentation ‘Standardized cell factories for production of biologically active, clinical-grade MSC-EVs’ as part of Session 10 on Manufacturing of EVs, on Day Three of the conference (October 26, 1130 hrs.).
EV production cell lines
The talk will highlight the role of Evercyte’s immortalized cell lines as production hosts for clinical-grade extracellular vesicles.
Evercyte’s hTERT immortalized cell lines maintain primary cell-like phenotype and characteristics while showing extended lifespan in vitro. These EV production cells include mesenchymal stromal cells derived from adipose tissue ASC/TERT300, bone marrow BM-MSC/TERT292, placental amnion P-MSC/TERT308, chorionic plate CP-MSC/TERT308, Wharton’s Jelly WJ-MSC/TERT273 and dental pulp DPSC/TERT334.
When compared to their primary counterparts, Evercyte’s telomerized MSC showed unchanged expression of canonical surface markers and maintained the multi-lineage differentiation potential. EVs isolated from telomerized and primary MSCs showed similar miRNA expression patterns, and absence of full-length hTERT mRNA, demonstrating limited effects of immortalization on EV characteristics. Moreover, telomerized MSC-derived EVs maintained anti-inflammatory, anti-fibrotic, wound healing, and pro-angiogenic properties, demonstrating the safe and promising use of telomerized MSC lines as hosts for standardized, reproducible, and scalable EV production.
Evercyte represented by Dr. Marieke Roefs, will take part in networking sessions to emphasize the production advantages of Evercyte cell lines, which are established under xeno-free conditions, with full documentation of any manipulation step and are therefore ready for transfer to a GMP facility for generation of a master cell bank that can be used for production of clinical grade vesicles.
She will also be promoting Evercyte’s extensive portfolio of other products and services, such as lab-scale production of EVs from customer-derived cells, enrichment and characterization of EVs, testing biological activity of EVs for characteristics such as anti-fibrotic, anti-inflammatory, neo-angiogenic, and wound-healing activities.
About Evercyte GmbH
Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel cell lines for production of extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.
The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalogue of readily available cell lines for the production of extracellular vesicles from mesenchymal stromal cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.
By providing native extracellular vesicles from mesenchymal stromal cells Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs e.g. tissue targeting and targeted drug delivery.
Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.
Learn more at: http://www.evercyte.com.
About MOVE 2023
MObility for Vesicles research in Europe is an active consortium of European National EV Societies (NEVS) formed to encourage closer European collaboration on extracellular vesicle and exosome research and knowledge sharing across different biological / biomedical disciplines.
MOVE’s inaugural symposium will be a four-day event opening October 24 at the Faculty of Law (Facultad de Derecho) of the University of Malaga in southern Spain.
The MOVE symposium is jointly organized by Spain’s GEIVEX, Germany’s GSEV, the British UKEV and Italian EVIta societies, with further information at: https://www.webcongreso.com/move.